Cannatrek was recognised in Deloitte’s annual Technology Fast 50 Australia Awards on Thursday night.
The company is building a facility at Lemnos.
Now in its 22nd year, the Deloitte Technology Fast 50 Australia program ranks the 50 fastest-growing technology companies in the country, with a minimum cumulative revenue of $8 million over a three-year period.
Deloitte recognised Cannatrek as one of Australia’s most successful technology innovators, ranking the company sixth on Deloitte’s Fast 50 Australia Awards for 2022.
Established in 2017, Cannatrek specialises in the research, cultivation, manufacture and delivery of plant-based medicine.
Cannatrek has been profitable for 24 consecutive months since November 2020 and has achieved 2990 per cent literal growth in revenue over the three financial years to 2022.
Founder and chief executive Tommy Huppert says the company is honoured to be recognised for its technological innovation.
“It is remarkable for us to receive this kind of recognition from outside our industry. We are thrilled to be counted as one of the country’s leading technology innovators,” he said.
Mr Huppert says Cannatrek’s unique, vertically integrated business model enables self-sufficiency across all elements of the supply chain, from cultivation to research to digital healthcare.
“Legislative approval for medicinal cannabis was only gained in 2016,” he said.
“Since then, the market has been expanding to meet increasing demand. We continually develop our technological capabilities to service a rapidly growing market.
“We use a blend of AI technology, telehealth, script management, digitally managed therapeutics and supply chains to service our diverse ecosystem of suppliers, doctors, pharmacists and patients.”
8°C